NEOGENOMICS INC NEO
Nasdaq · XNAS · stock · Services-Testing Laboratories
Chart by TradingView
4/9
Piotroski F — financial health
1.46
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $727.3M | -$108.0M | $314.3M | -$21.8M | $836.6M |
| 2024 | $660.6M | -$78.7M | $290.1M | -$34.0M | $902.3M |
| 2023 | $591.6M | -$88.0M | $244.6M | -$30.7M | $941.5M |
| 2022 | $509.7M | -$144.2M | $187.9M | -$96.9M | $998.0M |
| 2021 | $484.3M | -$8.3M | $187.1M | -$90.9M | $1.1B |
| 2020 | $444.4M | $4.2M | $185.9M | -$27.6M | $694.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| TETRAULT LYNN A. | director | 2026-06-15 | Sell | 5,307 | $11.10 |
| TETRAULT LYNN A. | director | 2026-06-09 | Sell | 5,307 | $11.29 |
| Kenny John P. | director | 2026-06-01 | Option exercise | 5,893 | — |
| Williams Felicia | director | 2026-06-01 | Option exercise | 23,077 | — |
| TETRAULT LYNN A. | director | 2026-06-01 | Option exercise | 23,077 | — |
| Perez David Brian | director | 2026-06-01 | Option exercise | 23,077 | — |
| Kelly Michael Aaron | director | 2026-06-01 | Option exercise | 23,077 | — |
| KANOVSKY STEPHEN M | director | 2026-06-01 | Option exercise | 23,077 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.46 (grey)
- Working capital / assets 0.212
- Retained earnings / assets -0.319
- EBIT / assets -0.085
- Equity / liabilities 1.599
Source: SEC EDGAR filings · CIK 0001077183 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.